Charles River Laboratories International, Inc. (NYSE: CRL) is a Healthcare company (Medical - Diagnostics & Research) with a market capitalization of $16.2B. The Maz Rating grades it against the other companies in its sector.
Charles River Laboratories International, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $337.97, Charles River Laboratories International, Inc. trades at 331.3x trailing earnings, 4.1x sales and 5.0x book value, with an EV/EBITDA of 64.3. Over the last twelve months it generated about $4.0B of revenue and $49M of net income. It runs a gross margin of 32.9%, an operating margin of 14.1% and a net margin of 1.0%. It shows return on equity of 1.3%, return on invested capital of -3.8% and a free cash flow yield of 2.5%. On the balance sheet: a debt-to-equity ratio of 0.88 and a current ratio of 1.41. Over the past 52 weeks the share price ranged from $146.20 to $379.63, with a beta of 1.34.
Charles River Laboratories International, Inc. does not currently pay a dividend.
37 Wall Street analyst ratings cover the stock: 1 Strong Buy, 27 Buy and 9 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Charles River Laboratories International, Inc. operates as a contract research organization (CRO), providing essential preclinical services to the pharmaceutical and biotechnology industries. Its core business revolves around assisting clients with drug discovery, non-clinical development, and thorough safety testing, with its services extending globally across the United States, Europe, Canada, and the Asia Pacific region. The company organizes its diverse offerings into three principal segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. 1. Research Models and Services (RMS): This division is a key supplier of high-quality rodent research models, including specially bred strains of rats and mice for experimental purposes. It also offers a comprehensive array of support services to help clients effectively utilize these models in their research and for the screening of potential non-clinical drug candidates. These include providing genetically engineered models, insourcing solutions for facility management, and diagnostic services for research animals. 2. Discovery and Safety Assessment (DSA): The DSA segment plays a crucial role in advancing early-stage drug pipelines. It delivers early-phase and in vivo discovery services focused on identifying and validating new therapeutic targets, chemical compounds, and antibodies. The ultimate goal is to prepare promising non-clinical drug and therapeutic candidates for subsequent safety evaluations. Additionally, this segment provides an extensive range of safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism studies, and pharmacokinetics. 3. Manufacturing Solutions: This segment addresses critical quality control requirements by offering in vitro methods for both routine and rapid testing of the quality of sterile and non-sterile pharmaceuticals, as well as consumer products. It also serves as a vital provider of specialized biologics testing, which is often outsourced by pharmaceutical and biotechnology companies. Furthermore, the segment supplies avian vaccine services, including specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products, all essential for vaccine production. Beyond these specialized segments, Charles River also manages contract vivarium operations, providing crucial animal housing and care facilities for its biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
It depends on the standard you follow. As of September 2026, Charles River Laboratories International, Inc. (CRL) passes 4 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global, Dow Jones and FTSE, and fails MSCI.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 16.4% / 30% · (Cash+Inv) / Mkt Cap (36m) 2.66% / 30% · Interest income / Revenue 0.10% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 16.4% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 1.35% / 33% · Receivables / Mkt Cap (36m) 4.94% / 49% · Interest income / Revenue 0.10% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 16.4% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 1.35% / 33.33% · Receivables / Mkt Cap (24m) 4.94% / 33.33% · Interest income / Revenue 0.10% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 34.6% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 2.67% / 33.33% · Receivables / Avg Assets (4Q) 9.57% / 33.33% · Interest income / Revenue 0.10% / 5% | Fail |
| FTSE | Debt / Total Assets 32.8% / 33.33% · (Cash+ST Inv) / Total Assets 2.69% / 33.33% · (Cash+Recv) / Total Assets 12.6% / 33.33% · Interest income / Revenue 0.10% / 5% | Pass |
It depends on the standard you follow. As of September 2026, Charles River Laboratories International, Inc. (CRL) passes 4 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global, Dow Jones and FTSE, and fails MSCI.
Yes. Charles River Laboratories International, Inc. is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
About 0.10% of each dividend: Charles River Laboratories International, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 26, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.